# Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes

> **NIH NIH R01** · YALE UNIVERSITY · 2022 · $679,061

## Abstract

Project Summary
Type 1 diabetes (T1D) is a chronic autoimmune disease that lead to the destruction of insulin producing β cells
over a period of years before clinical presentation and afterwards. However, not all β cells are killed since follow-
up studies of individuals with long standing T1D have identified residual insulin production even years after the
onset of disease. The premise of this work, based on these and other observations, is that there are adaptive
responses of the β cells to the immunologic attack that may prevent their destruction. We previously found that
some β cells undergo “dedifferentiation”, express lower levels of β cell transcription factors, have reduced
immunogenicity, and are protected from killing. The overall goal of this proposal is to identify adaptive changes
in β cells and use this information to enhance their survival in the setting of immune attack. We found that there
was increased expression of modifiers of the epigenome such as DNMT3a and Tet2 in human and murine β
cells in vitro, during exposure to inflammatory cytokines, or in vivo during autoimmunity. We found increased
expression of TET2 in β cells in islets from humans with autoimmune pancreatitis and T1D in nPOD samples.
However, from our analysis of β cells during diabetes progression in NOD mice, those that resist autoimmune
killing have decreased expression of Tet2. Tet2 induces hydroxymethylation of methylated CpG site which is the
first step in converting a repressive to permissive epigenetic mark. We created Tet2-/- NOD mice and in adoptive
transfer studies, bone marrow transplants and direct cultures with inflammatory cytokines and diabetogenic
immune cells showed that deletion of Tet2 prevents autoimmune killing of β cells. Our data indicates that the
Tet2-deficient β cells are not only resistant to immune killing but also modify the autoimmune responses. We
hypothesize that Tet2 can modify β cells and affect their susceptibility to autoimmune killing and plan to test this
hypothesis in murine model systems and human cells. We will analyze on a single cell basis the transcriptome
and epigenome (by ATACseq) of β cells from WT and Tet2-/- mice. We will identify the DNA binding sequences
of Tet2 in β cells. To specifically identify the role of Tet2 in β cells and determine the relationship between timing
of Tet2 expression and susceptibility to killing we will create mice with tissue specific deletion of Tet2 and induce
the deletion at times throughout the development of T1D. We will analyze the differences in immune cells in Tet2
sufficient and -/- mice. In the 2nd aim we will analyze TET2 expression and associated gene expression and
epigenetic signatures in human samples from nPOD, patients with autoimmune pancreatitis, and control
subjects. Finally, we will assess the role of TET2 expression in human embryonic stem cell-derived- β cells with
and without TET2 expression in vitro and after transplantation into mice. These studies will determin...

## Key facts

- **NIH application ID:** 10451626
- **Project number:** 5R01DK129523-02
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Kevan C Herold
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $679,061
- **Award type:** 5
- **Project period:** 2021-07-15 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10451626

## Citation

> US National Institutes of Health, RePORTER application 10451626, Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes (5R01DK129523-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10451626. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*